A mechanistic theory to explain the efficacy of antiretroviral therapy
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A mechanistic theory to explain the efficacy of antiretroviral therapy
Authors
Keywords
-
Journal
NATURE REVIEWS MICROBIOLOGY
Volume 12, Issue 11, Pages 772-780
Publisher
Springer Nature
Online
2014-09-29
DOI
10.1038/nrmicro3351
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation
- (2014) Timothy J. Henrich et al. ANNALS OF INTERNAL MEDICINE
- Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance
- (2013) S. Alireza Rabi et al. JOURNAL OF CLINICAL INVESTIGATION
- Increase in 2–Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial
- (2013) Hiroyu Hatano et al. JOURNAL OF INFECTIOUS DISEASES
- Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe
- (2013) A. De Luca et al. JOURNAL OF INFECTIOUS DISEASES
- Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant
- (2013) Deborah Persaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Antiretroviral Therapy and Prevalence of HIV Drug Resistance Mutations in Sweden 1997–2011
- (2013) Irene Bontell et al. PLoS One
- Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation
- (2013) K. A. Jurado et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time
- (2013) L. Josefsson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells
- (2013) Boghuma Titanji et al. Retrovirology
- Recent trends in HIV-1 drug resistance
- (2013) Janet D Siliciano et al. Current Opinion in Virology
- Single Cell Analysis of Lymph Node Tissue from HIV-1 Infected Patients Reveals that the Majority of CD4+ T-cells Contain One HIV-1 DNA Molecule
- (2013) Lina Josefsson et al. PLoS Pathogens
- Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
- (2013) Asier Sáez-Cirión et al. PLoS Pathogens
- No Evidence for Evolution of Protease Inhibitor Resistance from Standard Genotyping, After Three Years of Treatment with Darunavir/Ritonavir, With or Without Nucleoside Analogues
- (2012) Federico Pulido et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors
- (2012) Jacques J. Kessl et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Choreography of HIV-1 Proteolytic Processing and Virion Assembly
- (2012) Sook-Kyung Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antiretroviral dynamics determines HIV evolution and predicts therapy outcome
- (2012) Daniel I S Rosenbloom et al. NATURE MEDICINE
- A quantitative basis for antiretroviral therapy for HIV-1 infection
- (2012) Benjamin L Jilek et al. NATURE MEDICINE
- Maturation-Dependent HIV-1 Surface Protein Redistribution Revealed by Fluorescence Nanoscopy
- (2012) J. Chojnacki et al. SCIENCE
- Absence of HIV-1 Evolution in the Gut-Associated Lymphoid Tissue from Patients on Combination Antiviral Therapy Initiated during Primary Infection
- (2012) Teresa H. Evering et al. PLoS Pathogens
- Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study
- (2011) M. A. Valantin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy
- (2011) Viktor Dahl et al. JOURNAL OF INFECTIOUS DISEASES
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy
- (2011) Alex Sigal et al. NATURE
- Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis
- (2011) Sandra Mathis et al. PLoS One
- Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance
- (2011) M. E. S. Sampah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule
- (2011) L. Josefsson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy
- (2011) Maria Salgado et al. Retrovirology
- A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs
- (2011) L. Shen et al. Science Translational Medicine
- Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy
- (2010) Steven A Yukl et al. AIDS
- Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial
- (2010) J.-L. Meynard et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
- (2010) Maria J Buzón et al. NATURE MEDICINE
- Twenty-Five Years of Translational Medicine in Antiretroviral Therapy: Promises to Keep
- (2010) S. Broder Science Translational Medicine
- Raltegravir in the management of HIV-infected patients
- (2010) Hans-Juergen Stellbrink Drug Design Development and Therapy
- The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
- (2010) Rajesh T. Gandhi et al. PLOS MEDICINE
- HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review
- (2009) Wouter FW Bierman et al. AIDS
- The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
- (2009) Samuel Broder ANTIVIRAL RESEARCH
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
- (2009) J. B. Dinoso et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Challenge of Finding a Cure for HIV Infection
- (2009) D. D. Richman et al. SCIENCE
- A novel method for determining the inhibitory potential of anti-HIV drugs
- (2009) Lin Shen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Defining treatment failure in resource-rich settings
- (2009) Jeannette L Aldous et al. Current Opinion in HIV and AIDS
- Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
- (2008) Lin Shen et al. NATURE MEDICINE
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
- (2008) S. Palmer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle
- (2008) A. R. Sedaghat et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started